The risk factors of glycemic control, blood pressure control, lipid control in Chinese patients with newly diagnosed type 2 diabetes _ A nationwide prospective cohort study.
Adult
Aged
Aged, 80 and over
Blood Glucose
/ analysis
China
/ epidemiology
Cholesterol, LDL
/ blood
Combined Modality Therapy
Diabetes Mellitus, Type 2
/ blood
Dyslipidemias
/ complications
Female
Glycated Hemoglobin
/ analysis
Humans
Hypertension
/ complications
Hypoglycemia
/ chemically induced
Hypoglycemic Agents
/ adverse effects
Insulin
/ therapeutic use
Male
Middle Aged
Obesity
/ complications
Prevalence
Prospective Studies
Risk Factors
Smoking
/ epidemiology
Socioeconomic Factors
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
22 05 2019
22 05 2019
Historique:
received:
22
10
2018
accepted:
09
05
2019
entrez:
24
5
2019
pubmed:
24
5
2019
medline:
23
10
2020
Statut:
epublish
Résumé
Nationwide data on glycemic control, blood pressure (BP) control and lipid control in patients with newly diagnosed type 2 diabetes were vacant in China. The aim of this study was to assess the clinical outcomes for these patients. This is an observational prospective cohort study with 12 months of follow up. Patients with a diagnosis of type 2 diabetes less than 6 months were enrolled. Hemoglobin A1c (HbA1c) levels, BP levels and lipid levels were collected at baseline and the follow-ups. This study was registered at www.clinicaltrials.gov (NCT01525693). A total of 5770 participants from 79 hospitals across six geographic regions of China were recruited. After 12 months of treatment, 68.5% of these patients achieved HbA1c <7.0%; 83.7% reached BP <140/90 mmHg; 48.2% met low density lipoprotein cholesterol (LDL-c) <2.6 mmol/L; and 29.5% of patients reached the combined three therapeutic targets. Compared to those patients with baseline HbA1c <7.0%, patients with baseline HbA1c ≥7.0% had higher failure rate to reach glycemic control (relative risk (RR) = 2.04, p < 0.001), BP control (RR = 1.21, p < 0.001) and LDL-c control (RR = 1.11, p < 0.001). Obese patients had higher possibilities of failure in glucose control (RR = 1.05, p = 0.004), BP control (RR = 1.62, p < 0.001) and lipid control (RR = 1.09, p = 0.001) than patients with normal weight. The active smokers were more likely to fail in glycemic control than non-smokers (RR = 1.06, p = 0.002), and patients with physical activities were less likely to fail in lipid control than patients without exercises (RR = 0.93, p = 0.008). This study outlined the burdens of glycemic control, blood pressure control, lipid control in newly diagnosed type 2 diabetic patients in China, identified gaps in the quality of care and risk-factor control and revealed the factors influencing these gaps.
Identifiants
pubmed: 31118445
doi: 10.1038/s41598-019-44169-4
pii: 10.1038/s41598-019-44169-4
pmc: PMC6531462
doi:
Substances chimiques
Blood Glucose
0
Cholesterol, LDL
0
Glycated Hemoglobin A
0
Hypoglycemic Agents
0
Insulin
0
Banques de données
ClinicalTrials.gov
['NCT01525693']
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7709Références
Diabetes Obes Metab. 2018 Jun;20(6):1337-1341
pubmed: 29405543
Am J Med. 2013 Oct;126(10):925.e11-22
pubmed: 23810406
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
JAMA. 2017 Jun 27;317(24):2515-2523
pubmed: 28655017
Diabetes Metab Res Rev. 2016 Jul;32(5):442-58
pubmed: 27464265
JAMA. 2013 Sep 4;310(9):948-59
pubmed: 24002281
Diabetes Care. 2013 Aug;36(8):2271-9
pubmed: 23418368
PLoS One. 2016 Oct 17;11(10):e0164704
pubmed: 27749939
Lancet. 2008 Jan 12;371(9607):117-25
pubmed: 18191683
Eur Heart J. 2011 Oct;32(20):2525-32
pubmed: 21873710
Am J Clin Nutr. 2005 Jul;82(1 Suppl):222S-225S
pubmed: 16002825
Lancet Diabetes Endocrinol. 2014 Dec;2(12):935-43
pubmed: 25081582
Clin Exp Med. 2017 Feb;17(1):79-84
pubmed: 26695015
Diabetes Care. 2016 May;39(5):664-7
pubmed: 27208373
Diabetes Care. 2017 Nov;40(11):1425-1432
pubmed: 28801473
N Engl J Med. 2003 Jan 30;348(5):383-93
pubmed: 12556541
BMC Public Health. 2013 Jun 21;13:602
pubmed: 23800082
Diabetes Res Clin Pract. 2008 Dec;82(3):346-52
pubmed: 18926583
J Clin Lipidol. 2011 Mar-Apr;5(2):97-104
pubmed: 21392723
N Engl J Med. 2013 Apr 25;368(17):1613-24
pubmed: 23614587
N Engl J Med. 2010 Mar 25;362(12):1090-101
pubmed: 20335585
JAMA. 2009 May 27;301(20):2129-40
pubmed: 19470990
Diabetes Care. 2017 Jun;40(6):800-807
pubmed: 28404659
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
Lancet. 2010 Aug 7;376(9739):419-30
pubmed: 20594588
Hypertension. 2010 Dec;56(6):1060-8
pubmed: 20975031
N Engl J Med. 2008 Feb 7;358(6):580-91
pubmed: 18256393
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
N Engl J Med. 2008 Jun 12;358(24):2560-72
pubmed: 18539916
N Engl J Med. 2014 Oct 9;371(15):1392-406
pubmed: 25234206
BMJ Open Diabetes Res Care. 2015 Nov 19;3(1):e000135
pubmed: 26629347
BMJ. 1998 Sep 12;317(7160):703-13
pubmed: 9732337
Chin Med J (Engl). 2014;127(20):3524-9
pubmed: 25316223